TWD 70.8
(0.28%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 17.89 Million TWD | 13.83% |
2022 | 100.3 Million TWD | 7.66% |
2021 | 93.16 Million TWD | -18.05% |
2020 | 113.69 Million TWD | 0.15% |
2019 | 113.52 Million TWD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 34.24 Million TWD | -91.04% |
2024 Q1 | 34.41 Million TWD | 8.03% |
2023 Q3 | 31.85 Million TWD | 32.84% |
2023 FY | 114.17 Million TWD | 13.83% |
2023 Q2 | 23.98 Million TWD | -9.41% |
2023 Q1 | 26.47 Million TWD | -4.1% |
2023 Q4 | 31.85 Million TWD | 0.0% |
2022 FY | 100.3 Million TWD | 7.66% |
2022 Q4 | 27.6 Million TWD | 0.0% |
2021 FY | 93.16 Million TWD | -18.05% |
2020 FY | 113.69 Million TWD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Apex Biotechnology Corp. | 389.4 Million TWD | 95.404% |
Sinphar Pharmaceutical Co.,Ltd. | 807.86 Million TWD | 97.785% |
Panion & Bf Biotech Inc. | 817.56 Million TWD | 97.811% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 437.58 Million TWD | 95.91% |
GenMont Biotech Incorporation | 204.2 Million TWD | 91.236% |
Abnova (Taiwan) Corporation | 126.72 Million TWD | 85.877% |
Adimmune Corporation | 1.13 Billion TWD | 98.421% |
Tanvex BioPharma, Inc. | 2.16 Billion TWD | 99.172% |
Polaris Group | -3.06 Million TWD | 683.915% |
Energenesis Biomedical CO.,LTD. | 267.06 Million TWD | 93.299% |
PELL Bio-Med Technology Co. Ltd. | 385.1 Million TWD | 95.353% |